# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate o...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains ...
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthca...
JMP Securities analyst Jason Butler reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Market Outperform and maintains $...
Aquestive Therapeutics released topline pharmacokinetic data for Anaphylm (epinephrine) Sublingual Film for severe allergic rea...
Anaphylm pharmacokinetic results unaffected by oral cavity exposure to liquids of different temperatures and pHRemains on track...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains ...